Elidel® (Pimecrolimus) - Detailing from Skin Therapy Letter

 

Elidel® (Pimecrolimus)

 

 

  Content:

PATIENT PROFILE

 

 

Atopic Eczema

  • This is a chronic condition that varies in severity and fluctuates in intensity
  • Onset is in early childhood in most of cases
  • Estimates of the current incidence in school-aged children ranges between 7% and 21% in the United States.
  • The ideal treatment quickly brings the signs and symptoms of acute eczema under control and maintains the improvement safely for the long term

Long term control of Atopic Eczema

  • How to best use topical calcineurin inhibitors ?

There is currently a trend towards the use of topical calcineurin inhibitors as first line treatment. However these types of drugs are officially approved to be used only as second-line agents, when conventional therapies are deemed inadvisable (see section on indications)
It is suggested to use these drugs only for short periods of time, not continuously and to use the minimum amount amount needed to control the symptoms.
The use of these drugs in children younger than 2 years of age is not recommended at this time as their effect on the developing immune system is not known.


Next:   Dosing